Zentalis Pharmaceuticals (ZNTL) Net Cash Flow (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Net Cash Flow of -$4.1 million for Q1 2026, down 150.64% year-over-year from $8.0 million in Q1 2025, and down 32.11% quarter-over-quarter from -$3.1 million in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Net Cash Flow (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$4.1 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 150.64% year-over-year to -$4.1 million; the TTM figure through Mar 2026 stood at -$10.0 million (down 334.77% YoY), while the FY2025 annual figure was $2.1 million, down 63.95% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$4.1 million, down from -$3.1 million in the prior quarter.
- The five-year high for Net Cash Flow was $230.3 million in Q2 2023, with the low at -$155.8 million in Q3 2023.
- The 5-year median for Net Cash Flow is -$3.1 million (2025), against an average of -$1.6 million.
- Peak annual rise in Net Cash Flow reached 846.56% in 2023, while the deepest fall reached 16057.34% in 2023.
- Zentalis Pharmaceuticals' Net Cash Flow stood at $518000.0 in 2022, then slumped by 16057.34% to -$82.7 million in 2023, then soared by 91.02% to -$7.4 million in 2024, then soared by 58.53% to -$3.1 million in 2025, then tumbled by 32.11% to -$4.1 million in 2026.
- Business Quant data shows ZNTL's Net Cash Flow at -$4.1 million in Q1 2026, -$3.1 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | -7.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.15 Mn |
| Jun 30, 2026 | -7.15 Mn |
| Mar 31, 2026 | -4.07 Mn |
| Mar 31, 2026 | -4.07 Mn |
| Dec 31, 2025 | -3.08 Mn |
| Dec 31, 2025 | -3.08 Mn |
| Sep 30, 2025 | 1.47 Mn |
| Sep 30, 2025 | 1.47 Mn |
| Jun 30, 2025 | -4.33 Mn |
| Jun 30, 2025 | -4.33 Mn |
| Mar 31, 2025 | 8.03 Mn |
| Mar 31, 2025 | 8.03 Mn |
| Dec 31, 2024 | -7.42 Mn |
| Dec 31, 2024 | -7.42 Mn |
| Sep 30, 2024 | 4.29 Mn |
| Sep 30, 2024 | 4.29 Mn |
| Jun 30, 2024 | -640,000.00 |
| Jun 30, 2024 | -640,000.00 |
| Mar 31, 2024 | 9.58 Mn |
| Mar 31, 2024 | 9.58 Mn |